Essex Bio-Technology Limited

1061.HK

1061.HKEssex Bio-Technology Limited HK flag

Hong Kong Stock Exchange

2.79

HKD

+0.03

(+1.09%)

0.45EPS

6.20P/E

1.58BMarket Cap

Mar 27Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

KYG312371035

CUSIP

G31237103

Return %

Stock

S&P500

24.00

18.57

-40.38

40.07

-48.90

86.07

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Revenue per Share	0.38	0.48	0.62	0.93	1.17	1.38	1.6	2.06	2.21	1.69	2.84	2.3	2.99
Basic EPS, GAAP	0.06	0.07	0.1	0.14	0.19	0.24	0.3	0.4	0.52	0.38	0.6	0.39	0.48
Free Cash Flow per Basic Share	-0.04	-0.12	0.04	0.03	0.08	0.1	0.23	0.18	0.12	-0.03	0.27	0.17	0.37
Dividend per Share	0.01	0.01	0.01	0.02	0.02	0.02	0.06	0.06	0.07	0.05	0.09	0.09	0.07
Book Value per Share	0.23	0.28	0.36	0.45	0.62	0.84	1.07	1.4	1.82	2.13	2.64	2.92	3.34
Tangible Book Value per Share	0.26	0.32	0.41	0.53	0.66	0.85	1.05	1.21	1.35	1.38	1.55	1.19	1.4
Basic Weighted Avg Shares	557	557	557	557	560	560	562	571	579	578	577	574	570
Sales/Revenue/Turnover	213	267	347	518	654	776	900	1,176	1,279	978	1,638	1,318	1,707
Operating Margin (%)	18.33	18.68	21.57	19.17	20.23	21.33	20.98	22.11	25.71	22.51	25.21	21.36	18.26
Depreciation Expense	1	1	3	10	10	13	18	20	28	28	33	42	60
Net Income, GAAP	33	39	55	75	105	136	167	231	303	219	346	225	275
Effective Tax Rate (%)	17.26	21.46	24.86	21.39	19.71	16	15.1	15.37	14	12.73	12.29	13.42	20.45
Profit Margin (%)	15.61	14.59	15.82	14.52	16.04	17.57	18.6	19.64	23.64	22.38	21.13	17.11	16.13
Working Capital	86	27	47	124	151	312	438	547	758	727	858	653	435
LT Debt	- -	- -	- -	- -	- -	121	129	189	350	360	409	382	56
Total Equity	163	196	254	331	413	557	739	929	1,197	1,426	1,734	1,731	1,924
Return on Invested Capital (%)	21.06	17.49	19.26	22.57	24.96	23.28	19.45	21.35	20.71	10.72	16.61	10.54	10.86
Return on Capital (%)	28.02	22.45	23.63	28.37	30.44	28.18	25.23	27.11	25.56	13.67	18.24	11.07	13.03
Return on Common Equity (%)	28.02	27.31	31.1	33.43	35.06	33.49	31.22	32.93	32.61	19.14	25.12	14.1	15.38

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	20.35%	12.52%	29.51%
Net Income, GAAP	21.58%	9.71%	22.11%
Free Cash Flow	-75.29%	-204.7%	111.43%
Total Cash Common Dividend	30.01%	11.32%	-26.78%
Total Equity	22.89%	16.11%	11.11%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Dr. Mia Je Ngiam B.Sc.
Full Time Employees: 1,459
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: No. 88 Keji 6th Road Zhuhai People's Republic of China
IPO Date: Jun 27, 2001
Website: essexbio.com
Similar Companies: Hengkang Medical Group Co., Ltd. (002219.SZ)
Walvax Biotechnology Co., Ltd. (300142.SZ)
Marijuana Company of America, Inc. (MCOA)
Biofrontera Inc. (BFRIW)
Pure Extracts Technologies Corp. (PULL.CN)
Juva Life Inc. (JUVAF)
Business: Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Revenue per Share	0.38	0.48	0.62	0.93	1.17	1.38	1.6	2.06	2.21	1.69	2.84	2.3	2.99
Basic EPS, GAAP	0.06	0.07	0.1	0.14	0.19	0.24	0.3	0.4	0.52	0.38	0.6	0.39	0.48
Free Cash Flow per Basic Share	-0.04	-0.12	0.04	0.03	0.08	0.1	0.23	0.18	0.12	-0.03	0.27	0.17	0.37
Dividend per Share	0.01	0.01	0.01	0.02	0.02	0.02	0.06	0.06	0.07	0.05	0.09	0.09	0.07
Book Value per Share	0.23	0.28	0.36	0.45	0.62	0.84	1.07	1.4	1.82	2.13	2.64	2.92	3.34
Tangible Book Value per Share	0.26	0.32	0.41	0.53	0.66	0.85	1.05	1.21	1.35	1.38	1.55	1.19	1.4
Basic Weighted Avg Shares	557	557	557	557	560	560	562	571	579	578	577	574	570
Sales/Revenue/Turnover	213	267	347	518	654	776	900	1,176	1,279	978	1,638	1,318	1,707
Operating Margin (%)	18.33	18.68	21.57	19.17	20.23	21.33	20.98	22.11	25.71	22.51	25.21	21.36	18.26
Depreciation Expense	1	1	3	10	10	13	18	20	28	28	33	42	60
Net Income, GAAP	33	39	55	75	105	136	167	231	303	219	346	225	275
Effective Tax Rate (%)	17.26	21.46	24.86	21.39	19.71	16	15.1	15.37	14	12.73	12.29	13.42	20.45
Profit Margin (%)	15.61	14.59	15.82	14.52	16.04	17.57	18.6	19.64	23.64	22.38	21.13	17.11	16.13
Working Capital	86	27	47	124	151	312	438	547	758	727	858	653	435
LT Debt	- -	- -	- -	- -	- -	121	129	189	350	360	409	382	56
Total Equity	163	196	254	331	413	557	739	929	1,197	1,426	1,734	1,731	1,924
Return on Invested Capital (%)	21.06	17.49	19.26	22.57	24.96	23.28	19.45	21.35	20.71	10.72	16.61	10.54	10.86
Return on Capital (%)	28.02	22.45	23.63	28.37	30.44	28.18	25.23	27.11	25.56	13.67	18.24	11.07	13.03
Return on Common Equity (%)	28.02	27.31	31.1	33.43	35.06	33.49	31.22	32.93	32.61	19.14	25.12	14.1	15.38

Essex Bio-Technology Limited

Growth Rates

(avg. rate of change)

Company Description

Working Capital

Capital Structure

Growth Rates

(avg. rate of change)

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year

Year	Q1	Q2	Q3	Q4	FY
2021	- -	- -	- -	- -	1,638
2022	- -	- -	- -	- -	1,318
2023	- -	- -	- -	- -	1,707